Motley Fool Asset Management’s ADMA Biologics ADMA Stock Holding History

Motley Fool Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$762K	Sell	91,041 -9,653	-10%	-$88K	0.03%	169
2026 Q1	$907K	Sell	100,694 -6,895	-6%	-$109K	0.04%	163
2025 Q4	$1.96M	Buy	+107,589	New	+$1.81M	0.08%	152
2020 Q4	–	Sell	-718,797	Closed	-$1.6M	–	159
2020 Q3	$1.6M	Buy	718,797 +47,565	+7%	+$130K	0.14%	95
2020 Q2	$1.97M	Buy	671,232 +58,135	+9%	+$167K	0.2%	82
2020 Q1	$1.77M	Buy	613,097 +79,715	+15%	+$276K	0.23%	75
2019 Q4	$2.13M	Buy	533,382 +86,078	+19%	+$375K	0.23%	78
2019 Q3	$1.99M	Buy	447,304 +78,304	+21%	+$327K	0.23%	71
2019 Q2	$1.43M	Buy	+369,000	New	+$1.63M	0.16%	90

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Motley Fool Asset Management's ADMA Position: Q2 2026 in Review

Motley Fool Asset Management reduced its ADMA Biologics (ADMA) stake by 9.6% in Q2 2026, selling an estimated $88K and leaving 91,041 shares worth $762K. The position accounts for 0.03% of the portfolio, ranked #169.

Motley Fool Asset Management first reported a position in ADMA in Q2 2019 and has held it in 9 quarters since. The position peaked at $2.13M in Q4 2019. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Motley Fool Asset Management held 91,041 shares of ADMA Biologics worth $762K as of Q2 2026.
Motley Fool Asset Management sold 9,653 ADMA Biologics shares in Q2 2026, an estimated $88K.
ADMA Biologics made up 0.03% of Motley Fool Asset Management's portfolio in Q2 2026, its #169 holding.
Motley Fool Asset Management first reported a position in ADMA Biologics in Q2 2019 and has held it in 9 quarters since.
Motley Fool Asset Management's ADMA Biologics position peaked at $2.13M in Q4 2019.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.